Show results for
Refine by
Locations
- USA
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District Of Columbia
- Florida
- Georgia (Us)
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
Vascular Occlusion Equipment Supplied In Usa
4 equipment items found
Manufactured by:Okami Medical based inAliso Viejo,, CALIFORNIA (USA)
With this method, braided devices can be made with wires less than 20 microns in diameter – about ¼ the thickness of a human hair. Most vascular occluders rely on either a braided structure – one with relatively large wires and pores – or a polymer cover to disrupt flow. These approaches can lead to inconsistent occlusion or migration. ...
Manufactured by:Raumedic AG based inDietzenbach, GERMANY
During the application, the high-pressure tubing must withstand the forceful injection reliably, while remaining kink-free and flexible. This is the only way to safely diagnose pathological changes such as circulatory disorders and vascular ...
Manufactured by:Carbon Medical Technologies, Inc. based inSt. Paul, MINNESOTA (USA)
Durasphere is an injectable bulking agent containing pyrolytic carbon-coated graphite beads suspended in a water-based carrier gel containing beta glucan. It is used in the treatment of stress urinary incontinence. Durasphere is a highly biocompatible, permanent material that can be administered in less than 30 minutes in a simple office-based ...
Manufactured by:United Therapeutics Corporation based inSilver Spring, MARYLAND (USA)
Adcirca is a phosphodiesterase 5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH)(WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases ...